ADAMTS12 gene expression correlated with a shorter survival in NSCLC patients (p < 0.0001); similarly, the higher expression of the ADAMTS12 gene in patients with adenocarcinoma was associated with an almost two-fold reduction in survival time, i.e., from 113 months for a lower expression to 65 months for a higher expression (p < 0.0001). The gene discussed is ADAMTS12; the disease is non-small cell lung carcinoma.